ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015
PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MutScan: fast detection and visualization of target mutations by scanning FASTQ data.BMC bioinformatics · 2018Article
- Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors.Scientific reports · 2017Article
- Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting.Journal of Cancer · 2017Article
- Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.Oncotarget · 2016Article
- Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.Molecular diagnosis & therapy · 2016Article
- Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Oncotarget · 2015Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25559805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.